CGTX Stock Forecast: Cognition Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.58
−3.13% on the day

The median 12-month analyst price target for Cognition Therapeutics, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$55.3M
Ticker Nerd rank
47/ 100
Median analyst target
$3.00
Analysts covering
2
Revenue$0.0
Operating income−$4.2M
Net income−$3.9M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.4%
1M
−20.7%
YTD
−56.9%
1Y
−56.2%
From 52W high
−67.7%
From 52W low
0.0%
$0.58
$1.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Cognition Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
47/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
81
Accruals
63
Quality
53
Growth
49
Value
45
Issuance
26
Momentum
13
Volatility
13

Revisions (81): Analysts have, on balance, been raising their forecasts.

Volatility (13): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CGTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26CGTXHigh $4.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$3.00
Low
$3.00
Median
$4.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2026HC Wainwright & Co.ReiteratesBuy$3.00
27 Mar 2026Chardan CapitalMaintainsBuy$4.00
4 Dec 2025HC Wainwright & Co.ReiteratesBuy—
21 Nov 2025B. Riley SecuritiesReiteratesBuy—
19 Nov 2025HC Wainwright & Co.ReiteratesBuy—
8 Aug 2025Chardan CapitalMaintainsBuy—
26 June 2025HC Wainwright & Co.ReiteratesBuy—
27 May 2025HC Wainwright & Co.MaintainsBuy—
8 May 2025Chardan CapitalMaintainsBuy—
24 Mar 2025HC Wainwright & Co.MaintainsBuy—
21 Mar 2025Chardan CapitalMaintainsBuy—
26 Feb 2025Chardan CapitalMaintainsBuy—
19 Dec 2024B. Riley SecuritiesUpgradeBuy—
19 Dec 2024Chardan CapitalMaintainsBuy—
19 Dec 2024HC Wainwright & Co.MaintainsBuy—
27 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024Chardan CapitalMaintainsBuy—
4 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024Chardan CapitalMaintainsBuy—
12 Aug 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CGTX.

Market Radar

This page is one stock. Monday covers all of them.

CGTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CGTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Cognition Therapeutics, Inc. returned −56.2% against +6.9% for the S&P 500, dividends included.

CGTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26CGTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CGTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.9×

Cheaper than 46% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−48.6%

Higher than 22% of US stocks

Return on assets
−60.1%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cognition Therapeutics, Inc. has a market value of $55.3M and an enterprise value of $25.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$16.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$17.7M.

  • Shares outstanding: 95.1M.

  • Cognition Therapeutics, Inc. employs 14 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

CGTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGTXCognition Therapeutics, Inc.$55.3M47
CHRSCoherus Oncology, Inc.$55.3M38
AZRAzora Therapeutics, Inc.$55.0M16
OKYOOKYO Pharma Ltd.$55.0M26
AVXLAnavex Life Sciences Corp.$54.8M20
BOLDBoundless Bio, Inc.$54.8M93
NORDNordicus Partners Corp.$54.4M25

Take a look at CGTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Cognition Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CGTX

What is the CGTX stock price forecast for 2026-2027?

The median 12-month analyst price target for Cognition Therapeutics, Inc. is $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGTX stock a buy right now?

Of the 2 analysts covering Cognition Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cognition Therapeutics, Inc. 47 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGTX?

As at 21 Nov 2026, Cognition Therapeutics, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (81 of 100).

Will CGTX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $3, and Ticker Nerd's factor model ranks Cognition Therapeutics, Inc. 47 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGTX stock forecast for 2030?

No analyst covering Cognition Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has CGTX stock performed over the past year?

Cognition Therapeutics, Inc. returned -56.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cognition Therapeutics, Inc. do?

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for age-related degenerative diseases affecting the central nervous system and the retina. Its lead program centers on zervimesine (CT1812), an oral candidate designed to protect neuronal synapses and modulate disease-related protein interactions.

Company

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for age-related degenerative diseases affecting the central nervous system and the retina. Its lead program centers on zervimesine (CT1812), an oral candidate designed to protect neuronal synapses and modulate disease-related protein interactions. The company is evaluating this candidate across multiple neuroscience and neuro-ophthalmology settings, including Alzheimer’s disease, mild cognitive impairment, dementia with Lewy bodies, and geographic atrophy associated with dry age-related macular degeneration. Cognition Therapeutics combines mechanistic research with translational and clinical development to address disorders linked to synaptic dysfunction and cellular stress. Headquartered in Purchase, New York, the company plays a specialized role in the biotech market as a developer of targeted treatments for complex neurodegenerative and retinal conditions.

CEO Ms. Lisa Ricciardi · 14 employees · United States · https://www.cogrx.com